ZEMURON SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

ROCURONIUM BROMIDE

Доступна с:

MERCK CANADA INC

код АТС:

M03AC09

ИНН (Международная Имя):

ROCURONIUM BROMIDE

дозировка:

10MG

Фармацевтическая форма:

SOLUTION

состав:

ROCURONIUM BROMIDE 10MG

Администрация маршрут:

INTRAVENOUS

Штук в упаковке:

10X5ML

Тип рецепта:

Prescription

Терапевтические области:

NEUROMUSCULAR BLOCKING AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0126317001; AHFS:

Статус Авторизация:

CANCELLED POST MARKET

Дата Авторизация:

2018-02-05

Характеристики продукта

_ _
_Page 1 of 35_
PRODUCT MONOGRAPH
ZEMURON
®
Rocuronium Bromide
10 mg/mL Solution for Injection
_ _
Non-depolarizing Skeletal Neuromuscular Blocking Agent
MERCK CANADA INC.
Date of Revision:
16750 route Transcanadienne
November 5, 2018
Kirkland, QC Canada H9H 4M7
www.merck.ca
Submission Control No: 220017
_ _
_ _
_ _
_ _
_Page 2 of 35_
_ _
TABLE OF CONTENTS
[To create the table of contents, select from the
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................
12
DOSAGE AND ADMINISTRATION
.....................................................................................
13
OVERDOSAGE
.......................................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 18
STORAGE AND STABILITY
.................................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 26
PART II: SCIENTIFIC INFORMATION
...............................................................................28
PHARMACEUTI